Open an account

State Street SPDR S&P Biotech ETF

XBI · ETF

$149.54−$2.10 (−1.38%)TodayMarket closed ·
Prev close $151.64

About XBI

XBI was created on 2006-01-31 by SPDR. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 10372.96m in AUM and 159 holdings. XBI tracks an equal-weighted index of US biotechnology stocks.

Issuer
SPDR
Tracks
S&P Biotechnology Select Industry
Expense ratio
0.35%
Assets under management
$10.62B
Inception
Jan 31, 2006
Asset class
Equity
Website
ssga.com

XBI key statistics

Market cap
0
Price-earnings ratio
0.00
Average volume
10.32M
Volume
6.61M
Open price
$150.50
High today
$150.71
Low today
$147.64
52 Week high
$169.89
52 Week low
$106.30

State Street SPDR S&P Biotech ETF (XBI) at a glance

State Street SPDR S&P Biotech ETF (XBI) last traded at $149.54, with a market cap of 0 and a price-to-earnings ratio of 0.00.

Today the fund has traded between $147.64 and $150.71. The current price is 1.3% above the day's low and 0.8% below its high.

Volume so far is 6.61M shares, below the average of 10.32M shares a day.

Over the past year State Street SPDR S&P Biotech ETF has ranged from $106.30 to $169.89, and now sits 68% of the way up that range.

XBI news

  • Piero Cingari

    Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today

  • Chandrima Sanyal

    Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach

  • Piero Cingari

    Economy Grows 63% in Six Years, 30-Year Treasury Lost Almost As Much

  • Chandrima Sanyal

    Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets

  • Chandrima Sanyal

    Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back

  • Henry Khederian

    What's Going On With Novavax Stock?

  • Chandrima Sanyal

    Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

  • Henry Khederian

    Novavax Stock Climbs Monday: What's Going On?

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.